Experimental Medicine Approaches in Early-Phase CNS Drug Development
Related Experiment Video
Updated: Aug 6, 2025
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
Published on: August 16, 2010
Brett A English1, Larry Ereshefsky2
1Clinical Sciences at CenExel, Brentwood, TN, USA.
Abstract:
Traditionally, Phase 1 clinical trials were largely conducted in healthy normal volunteers and focused on collection of safety, tolerability, and pharmacokinetic data. However, in the CNS therapeutic area, with more drugs failing in later phase development, Phase 1 trials have undergone an evolution that includes incorporation of novel approaches involving novel study designs, inclusion of biomarkers, and early inclusion of patients to improve the pharmacologic understanding of novel CNS-active compounds early in clinical development with the hope of improving success in later phase pivotal trials. In this chapter, the authors will discuss the changing landscape of Phase 1 clinical trials in CNS, including novel trial methodology, inclusion of pharmacodynamic biomarkers, and experimental medicine approaches to inform early decision-making in clinical development.
Insights
Phase 1 clinical trials for central nervous system (CNS) drugs now include patients and biomarkers. This evolution aims to improve understanding of CNS-active compounds and enhance success in later trial phases.
Area of Science:
- Clinical Pharmacology
- Neuroscience Drug Development
- Biomarker Research
Background:
- Phase 1 trials traditionally focused on safety and pharmacokinetics in healthy volunteers.
- Central nervous system (CNS) drug development faces high failure rates in later phases.
- This necessitates an evolution in early-phase trial design.
Purpose of the Study:
- To discuss the evolving landscape of Phase 1 clinical trials in the CNS therapeutic area.
- To highlight novel methodologies and approaches being incorporated.
- To improve early pharmacologic understanding of CNS-active compounds.
Main Methods:
- Incorporation of novel study designs.
- Inclusion of pharmacodynamic biomarkers.
- Early inclusion of patients in Phase 1 trials.
- Application of experimental medicine approaches.
Main Results:
- The abstract does not contain results, it is a chapter discussing changes in trial design.
Conclusions:
- Phase 1 CNS trials are shifting towards earlier patient involvement and biomarker integration.
- These changes aim to enhance early decision-making and improve the success rate of CNS drug development.
- Novel trial designs and experimental medicine approaches are key to this evolution.
More Related Videos
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
07:41Author Spotlight: Establishing Mixed Neuronal and Glial Cell Cultures from Embryonic Mouse Brains to Study Infection and Innate Immunity
Published on: June 30, 2023
